- Home
- SNCY vs ORIC Comparison
SNCY vs ORIC Comparison
Compare SNCY & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNCY | ORIC |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.0M | 837.3M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SNCY | ORIC |
|---|---|---|
| Price | $18.02 | $10.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $19.50 | ★ $19.73 |
| AVG Volume (30 Days) | 556.4K | ★ 2.4M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $1,126,769,000.00 | N/A |
| Revenue This Year | $11.29 | N/A |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | $18.73 | ★ N/A |
| Revenue Growth | ★ 4.74 | N/A |
| 52 Week Low | $8.10 | $4.52 |
| 52 Week High | $22.29 | $14.93 |
Technical Indicators
Market Signals| Indicator | SNCY | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 58.16 | 46.30 |
| Support Level | $16.93 | $9.75 |
| Resistance Level | $18.18 | $10.79 |
| Average True Range (ATR) | 0.67 | 1.04 |
| MACD | 0.22 | 0.03 |
| Stochastic Oscillator | 75.99 | 50.77 |
Price Performance
Historical ComparisonAbout SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.